SunTrust Reduces Galmed Pharmaceuticals Price Target From $19 To $15 Based On Results And Implications On Read-Out Of PHase IIB ARREST Study; Lowered Probability Of Success For aramchol In Their DCF, NPV Models From 25% To 20%